deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT04853017

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors

Sponsor: Elicio Therapeutics

Conditions Bile Duct Cancer Cholangiocarcinoma Colorectal Cancer Gallbladder Carcinoma KRAS G12D KRAS G12R Minimal Residual Disease NRAS G12D NRAS G12R Non-small Cell Lung Cancer Ovarian Cancer Pancreatic Ductal Adenocarcinoma
Interventions ELI-002 2P
Updated 34 times since 2021 Last updated: Aug 19, 2025 Started: Oct 4, 2021 Primary completion: Jan 26, 2023 Completion: Sep 24, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bile Duct Cancer and Cholangiocarcinoma, this trial is completed. The trial is conducted by Elicio Therapeutics and has accumulated 34 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 10 months · monthly snapshot

Change History

34 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 29 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE1

  6. Oct 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE1

  7. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1

  8. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE1

  9. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1

  10. Jun 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1

  11. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  12. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE1

  13. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  14. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1

  15. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  20. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  21. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1

  22. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1

  23. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

  24. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

  25. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  26. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

    Phase: PHASE1_PHASE2 → PHASE1

  27. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  28. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  29. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Elicio Therapeutics
Data source: Elicio Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations